Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital.
Niamh CunninghamScott ShepherdKabir MohammedKarla A LeeMark AllenStephen JohnstonEmma KippsSophie McGrathJillian NobleMarina PartonAlistair RingNicholas C TurnerAlicia F C OkinesPublished in: Breast cancer research and treatment (2022)
Neratinib monotherapy or in combination with capecitabine is a useful treatment for patients with and without brain metastases. PFS and OS were found to be similar as previous trial data. Routine anti-diarrhoeal prophylaxis allows this combination to be safely delivered to patients in a real-world setting.
Keyphrases
- positive breast cancer
- brain metastases
- end stage renal disease
- small cell lung cancer
- ejection fraction
- newly diagnosed
- chronic kidney disease
- healthcare
- combination therapy
- clinical trial
- peritoneal dialysis
- prognostic factors
- emergency department
- electronic health record
- randomized controlled trial
- open label
- big data
- radiation therapy
- data analysis
- artificial intelligence
- locally advanced
- adverse drug
- drug induced